Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.61

-0.6%

Nov 6 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: LLCF who wrote (5956)	3/20/2002 10:30:43 AM
From: aknahow	Read Replies (2) of 52153

Reading the two articles in the Scientist is a must. Apparently while tumors do not shrink enough to meet endpoints of trials the patients lived longer because the starved tumors were unable to replicate. So perhaps with trials designed with other endpoints would better capture the real potential of anti-angiogensis drugs. So tumor size does not matter but movement, staying alive does. Read the articles and draw your own conclusions. Anti-angiogenic drugs used for diabetic retinolpathy appear to offer promise.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next